Agios Pharma (AGIO) Tops Q3 EPS by 20c

Agios Pharma (NASDAQ: AGIO) reported Q3 EPS of ($1.59), $0.20 better than the analyst estimate of ($1.79). Revenue for the quarter came in at $11.4 million versus the consensus estimate of $9.77 million.

For earnings history and earnings-related data on Agios Pharma (AGIO) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 21c
• FGI Industries Ltd (FGI) Tops Q2 EPS by 59c